GOGeorge Johan Arnold Offerhaus

George Johan Arnold Offerhaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


George Johan Arnold Offerhaus has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Folkert H. M. Morsink

    Department of Pathology, University Medical Center, 3508 GA, Utrecht, The Netherlands

    3 shared publications
  • Anya N. A. Milne

    From the Department of Pathology, University Medical Center, Utrecht, the Netherlands (Ms Ottenhof, Drs Milne, ten Kate, and Offerhaus, and Mr Morsink); the Department of Pathology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (Dr Drillenburg); and the Department of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institution, Baltimore, Maryland (Dr Maitra)

    2 shared publications
  • Fiebo J. W. Ten Kate

    From the Department of Pathology, University Medical Center, Utrecht, the Netherlands (Ms Ottenhof, Drs Milne, ten Kate, and Offerhaus, and Mr Morsink); the Department of Pathology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (Dr Drillenburg); and the Department of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institution, Baltimore, Maryland (Dr Maitra)

    2 shared publications
  • Niki A. Ottenhof

    From the Department of Pathology, University Medical Center, Utrecht, the Netherlands (Ms Ottenhof, Drs Milne, ten Kate, and Offerhaus, and Mr Morsink); the Department of Pathology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (Dr Drillenburg); and the Department of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institution, Baltimore, Maryland (Dr Maitra)

    2 shared publications
  • Paul Drillenburg

    From the Department of Pathology, University Medical Center, Utrecht, the Netherlands (Ms Ottenhof, Drs Milne, ten Kate, and Offerhaus, and Mr Morsink); the Department of Pathology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (Dr Drillenburg); and the Department of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institution, Baltimore, Maryland (Dr Maitra)

    2 shared publications
  • Anirban Maitra

    From the Department of Pathology, University Medical Center, Utrecht, the Netherlands (Ms Ottenhof, Drs Milne, ten Kate, and Offerhaus, and Mr Morsink); the Department of Pathology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands (Dr Drillenburg); and the Department of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institution, Baltimore, Maryland (Dr Maitra)

    1 shared publication

Latest Publications

  • Open Access

    High-Throughput Sequencing of Gastric Cancer Patients: Unravelling Genetic Predispositions Towards an Early-Onset Subtype

    by Julita Machlowska, Przemysław Kapusta, Jacek Baj, Folkert H. M. Morsink, Paweł Wołkow, Ryszard Maciejewski, G. Johan A. Offerhaus, Robert Sitarz

    Background: Gastric cancer is the fourth most common cause of cancer-related death. Currently, it is broadly accepted that the molecular complexity and heterogeneity of gastric cancer, both inter- and intra-tumor, display important barriers for finding specific biomarkers for the early detection and diagnosis of this malignancy. Early-onset gastric cancer is not as prevalent as conventional gastric carcinoma, but it is a preferable model for studying the genetic background, as young patients are less exposed to environmental factors, which influence cancer development. Aim: The main objective of this study was to reveal age-dependent genotypic characteristics of gastric cancer subtypes, as well as conduct mutation profiling for the most frequent alterations in gastric cancer development, using targeted next-generation sequencing technology. Patients and methods: The study group included 53 patients, consisting of 18 patients with conventional gastric cancer and 35 with an early-onset subtype. The DNA of all index cases was used for next-generation sequencing, employing a panel of 94 genes and 284 single nucleotide polymorphisms (SNPs) (TruSight Cancer Panel, Illumina), which is characteristic for common and rare types of cancer. Results: From among the 53 samples processed for sequencing, we were able to identify seven candidate genes (STK11, RET, FANCM, SLX4, WRN, MEN1, and KIT) and nine variants among them: one splice_acceptor, four synonymous, and four missense variants. These were selected for the age-dependent differentiation of gastric cancer subtypes. We found four variants with C-Score ≥ 10, as 10% of the most deleterious substitutions: rs1800862 (RET), rs10138997 (FANCM), rs2230009 (WRN), and rs2959656 (MEN1). We identified 36 different variants, among 24 different genes, which were the most frequent genetic alterations among study subjects. We found 16 different variants among the genes that were present in 100% of the total cohort: SDHB (rs2746462), ALK (rs1670283), XPC (rs2958057), RECQL4 (rs4925828; rs11342077, rs398010167; rs2721190), DDB2 (rs326212), MEN1 (rs540012), AIP (rs4930199), ATM (rs659243), HNF1A (rs1169305), BRCA2 (rs206075; rs169547), ERCC5 (rs9514066; rs9514067), and FANCI (rs7183618). Conclusions: The technology of next-generation sequencing is a useful tool for studying the development and progression of gastric carcinoma in a high-throughput way. Our study revealed that early-onset gastric cancer has a different mutation frequency profile in certain genes compared to conventional subtype.


  • Open Access

    Associations of Epstein-Barr Virus-Positive Gastric Adenocarcinoma with Circulating Mediators of Inflammation and Immune Response

    by M. Constanza Camargo, Armands Sivins, Sergejs Isajevs, Valdis Folkmanis, Dace Rudzīte, Margaret L. Gulley, G. Johan Offerhaus, Marcis Leja, Charles S. Rabkin

    Epstein-Barr virus (EBV)-positive gastric adenocarcinoma exhibits locally intense inflammation but systemic manifestations are uncertain. Our study examined whether circulating mediators of inflammation and immune response differ by tumor EBV status. From a Latvian series of 302 gastric cancer cases, we measured plasma levels of 92 immune-related proteins in the 28 patients with EBV-positive tumors and 34 patients with EBV-negative tumors. Eight markers were statistically significantly higher with tumor EBV positivity: chemokine C-C motif ligand (CCL) 20 (Odds Ratio (OR) = 3.6; p-trend = 0.001), chemokine C-X-C motif ligand 9 (OR = 3.6; p-trend = 0.003), programmed death-ligand 1 (PD-L1; OR = 3.4; p-trend = 0.004), interleukin (IL)-10 (OR = 2.4; p-trend = 0.019), CCL19 (OR = 2.3; p-trend = 0.019), CCL11 (OR = 2.2; p-trend = 0.026), IL-17A (OR = 2.0; p-trend = 0.038) and CCL8 (OR = 1.9; p-trend = 0.049). Systemic responses to EBV-positive gastric cancer are characterized by alterations in chemokines and PD-L1. Profiling of these molecules may enable non-invasive diagnosis of EBV status when tumor tissue is unavailable. Our findings provide theoretical justification for clinical evaluations of immune checkpoint therapy for EBV-positive gastric cancer.


  • Open Access

    Stem cell dynamics and pretumor progression in the intestinal tract

    by Huiying Ma, Folkert H. M. Morsink, George Johan Arnold Offerhaus, Wendy W. J. de Leng

    Colorectal carcinogenesis is a process that follows a stepwise cascade that goes from the normal to an invisible pretumor stage ultimately leading to grossly visible tumor progression. During pretumor progression, an increasing accumulation of genetic alterations occurs, by definition without visible manifestations. It is generally thought that stem cells in the crypt base are responsible for this initiation of colorectal cancer progression because they are the origin of the differentiated epithelial cells that occupy the crypt. Furthermore, they are characterized by a long life span that enables them to acquire these cumulative mutations. Recent studies visualized the dynamics of stem cells both in vitro and in vivo. Translating this work into clinical applications will contribute to the evaluation of patients’ predisposition for colorectal carcinogenesis and may help in the design of preventive measures for high-risk groups. In this review, we outline the progress made in the research into tracing stem cell dynamics. Further, we highlight the importance and potential clinical value of tracing stem cell dynamics in pretumor progression.


  • Open Access

    A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome

    by Els van Riel, Margreet Gem Ausems, Frans Bl Hogervorst, Irma Kluijt, Marielle E van Gijn, Jeanne van Echtelt, Karen Scheidel-Jacobse, Eric Fam Hennekam, Rein P Stulp, Yvonne J Vos, et al.

    An unclassified variant (UV) in exon 1 of the MLH1 gene, c.112A > C, p.Asn38His, was found in six families who meet diagnostic criteria for Lynch syndrome. The pathogenicity of this variant was unknown. We aim to elucidate the pathogenicity of this MLH1 variant in order to counsel these families adequately and to enable predictive testing in healthy at-risk relatives.


  • Open Access

    Pancreatic Intraepithelial Neoplasia and Pancreatic Tumorigenesis: Of Mice and Men

    by Niki A. Ottenhof, Anya N. A. Milne, Folkert H. M. Morsink, Paul Drillenburg, Fiebo J. W. Ten Kate, Anirban Maitra, G. Johan Offerhaus

    Context. —Pancreatic cancer has a poor prognosis with a 5-year survival of less than 5%. Early detection is at present the only way to improve this outlook. This review focuses on the recent advances in our understanding of pancreatic carcinogenesis, the scientific evidence for a multistaged tumor progression, and the role genetically engineered mouse models can play in recapitulating the natural course and biology of human disease. Objectives. —To illustrate the stepwise tumor progression of pancreatic cancer and genetic alterations within the different stages of progression and to review the findings made with genetically engineered mouse models concerning pancreatic carcinogenesis. Data Sources. —A review of recent literature on pancreatic tumorigenesis and genetically engineered mouse models. Conclusions. —Pancreatic cancer develops through stepwise tumor progression in which preinvasive stages, called pancreatic intraepithelial neoplasia, precede invasive pancreatic cancer. Genetic alterations in oncogenes and tumor suppressor genes underlying pancreatic cancer are also found in pancreatic intraepithelial neoplasia. These mutations accumulate during progression through the consecutive stages of pancreatic intraepithelial neoplasia lesions. Also in genetically engineered mouse models of pancreatic ductal adenocarcinoma, tumorigenesis occurs through stepwise progression via consecutive mouse pancreatic intraepithelial neoplasia, and these models provide important tools for clinical applications. Nevertheless differences between mice and men still remain.


  • Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men

    by Niki A. Ottenhof, Anya N. A. Milne, Folkert H. M. Morsink, Paul Drillenburg, Fiebo J. W. Ten Kate, Anirban Maitra, G. Johan Offerhaus

    Context.-Pancreatic cancer has a poor prognosis with a 5-year survival of less than 5%. Early detection is at present the only way to improve this outlook. This review focuses on the recent advances in our understanding of pancreatic carcinogenesis, the scientific evidence for a multistaged tumor progression, and the role genetically engineered mouse models can play in recapitulating the natural course and biology of human disease. Objectives.-To illustrate the stepwise tumor progression of pancreatic cancer and genetic alterations within the different stages of progression and to review the findings made with genetically engineered mouse models concerning pancreatic carcinogenesis. Data Sources.-A review of recent literature on pancreatic tumorigenesis and genetically engineered mouse models. Conclusions.-Pancreatic cancer develops through stepwise tumor progression in which preinvasive stages, called pancreatic intraepithelial neoplasia, precede invasive pancreatic cancer. Genetic alterations in oncogenes and tumor suppressor genes underlying pancreatic cancer are also found in pancreatic intraepithelial neoplasia. These mutations accumulate during progression through the consecutive stages of pancreatic intraepithelial neoplasia lesions. Also in genetically engineered mouse models of pancreatic ductal adenocarcinoma, tumorigenesis occurs through stepwise progression via consecutive mouse pancreatic intraepithelial neoplasia, and these models provide important tools for clinical applications. Nevertheless differences between mice and men still remai


  • Open Access

    Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)

    by M van Heijl, Jjb van Lanschot, Lb Koppert, Mi van Berge Henegouwen, K Muller, Ew Steyerberg, H van Dekken, Bpl Wijnhoven, Hw Tilanus, Dj Richel, et al.

    A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases (cT1-3 N0-1 M0). A high percentage of irradical resections is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone and in trials in which patients are treated with surgery alone. Improvement of locoregional control by using neoadjuvant chemoradiotherapy might therefore improve the prognosis in these patients. We previously reported that after neoadjuvant chemoradiotherapy with weekly administrations of Carboplatin and Paclitaxel combined with concurrent radiotherapy nearly always a complete R0-resection could be performed. The concept that this neoadjuvant chemoradiotherapy regimen improves overall survival has, however, to be proven in a randomized phase III trial.


  • Grading gastrointestinal dysplasia and what to call it when you don't know what it is

    by Gj Offerhaus

    Dysplasia in the gastrointestinal tract is defined as intraepithelial neoplasia (IEN) according to the WHO nomenclature. Neoplastic growth in the gastrointestinal tract evolves through stepwise tumour progression in which consecutive morphological stages are characterized by increasing genetic instability accompanied by specific genetic alterations. Invasive cancer is preceded by non‐invasive precursor stages and the clonal epithelial cell proliferation in these pre‐invasive stages is diagnosed as dysplasia or IEN. Dysplasia is therefore a marker for cancer risk and guides surveillance. Dysplasia is conventionally graded using a two‐tier system and low‐ and high‐grade dysplasia convey different connotations regarding cancer risk. This perspective argues that the critical differential diagnosis is the one between neoplastic and non‐neoplastic epithelial cell proliferations and the relevance of grading dysplasia is questionable. It is furthermore expected that a molecular signature will predict the propensity to invasive carcinoma more accurately than routine histopathology in the near future. Research in this field needs to focus on a combination of biomarkers representing genetic instability, clonal mutations, and genetic clonal divergence. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.